{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', \"See Section 3.2.3 for rationale regarding doses and schedules for Investigator's Choice options.\", 'For pemetrexed, topotecan, irinotecan, gemcitabine, and vinorelbine, instructions for storage,', 'handling, and administration are to be found in the appropriate Summary of Product', 'Characteristics or package insert or pharmacy reference sheets.', 'For the IC options, doses are weight-based. For cycle 1/day 1, the investigator should use', 'screening height and weight to calculate dose, but cycle 1/day 1weight is also allowed to be used,', 'per investigator discretion. Weight is measured at start of each cycle. If there is a >10% change', 'in weight, the IC chemotherapy dose should be re-calculated.', '8.1.2.1.', 'Pemetrexed, Alimta R', 'Drug Class and Mechanism of Action', 'Pemetrexed is a folate analogue that inhibits multiple enzymes involved in both purine and', 'pyrimidine synthesis, including thymidylate synthase, dihydrofolate reductases, and glycinamide', 'ribonucleotide formyl transferase. Pemetrexed is not metabolized to an appreciable extent, and is', 'primarily eliminated in the urine.', 'Supplier/How Handled', 'See pharmacy manual.', 'Solution Preparation', 'See pharmacy manual.', 'Storage/Stability', 'See pharmacy manual.', 'Administration', 'Pemetrexed will be administered at a dose of 500 mg/m\u00b2 as an IV infusion over 10 minutes', '(=5 minutes) on day 1 of each 21-day cycle (Lorusso 2010) for up to 96 weeks of treatment. See', 'Section 3.2.3 for rationale in support of IC chemotherapy regimens.', 'To reduce toxicity, patients treated with pemetrexed must be instructed to take a low dose oral', 'folic acid preparation or multivitamin with folic acid on a daily basis (usual dose, 400 g/day;', 'range, 350 g/day to 1000 g/day). At least 5 daily doses of folic acid must be taken in the 7-day', 'period preceding the first dose of pemetrexed. Daily folic acid dosing should continue during the', 'entire period of pemetrexed treatment and for 21 days after the last dose of pemetrexed. Patients', 'must also receive 1 intramuscular injection of 1000 g vitamin B12 in the week preceding the first', 'dose of pemetrexed, and with every third pemetrexed dose thereafter (every 9 weeks, if no delays', 'in pemetrexed dosing). Subsequent 1000 g vitamin B12 injections may be given on the same day', 'as pemetrexed infusions.', 'Regeneron Pharmaceuticals, Inc.', 'Page 68 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Adverse Effects', 'See FDA/European Medicines Agency (EMA)-approved (or local equivalent) pemetrexed', 'prescribing information for a comprehensive list of AEs associated with pemetrexed.', '8.1.2.2. Topotecan', 'Drug Class and Mechanism of Action', 'Topotecan is a cell cycle-specific inhibitor of the nuclear enzyme topoisomerase I. It has a mean', \"half-life of approximately 3 hours. Topotecan's metabolism and clearance are complex but it is\", 'estimated that approximately 40% of the drug undergoes renal clearance.', 'Supplier/How Supplied', 'See pharmacy manual.', 'Solution Preparation', 'See pharmacy manual.', 'Storage/Stability', 'See pharmacy manual.', 'Administration', 'Topotecan 1 mg/m\u00b2 will be administered by IV infusion over 30 minutes (10 minutes) daily for', '5 consecutive days, starting on day 1 of a 21-day course (Bookman 2000) for up to 96 weeks of', 'treatment. See Section 3.2.3 for rationale in support of IC chemotherapy regimens. For patients', 'who do not experience significant toxicity with the first course of topotecan, subsequent courses', 'may be increased to topotecan 1.25 mg/m\u00b2 daily X 5 days, every 21 days.', 'Adverse effects', 'See FDA/EMA-approved (or local equivalent) topotecan prescribing information for a', 'comprehensive list of AEs associated with topotecan.', '8.1.2.3.', 'Irinotecan', 'Drug Class and Mechanism of Action', 'Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme', 'topoisomerase 1, which relieves torsional strain in DNA by inducing reversible single-strand', 'breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase 1-DNA complex and', 'prevent relegation of these single strand breaks. Cytotoxicity of irinotecan is thought be due to', 'double-stranded damage during DNA synthesis when replication enzymes interaction with ternary', 'complex formed by DNA/topoisomerase 1/irinotecan or SN-38. Mammalian cells cannot efficient', 'repair these double-strand breaks.', 'Supplier/How Supplied', 'See pharmacy manual.', 'Stability/Storage', 'See pharmacy manual.', 'Regeneron Pharmaceuticals, Inc.', 'Page 69 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}